BioMarin Pharmaceutical Inc. To Present At Upcoming Investor Conferences
BioMarin Pharmaceutical Inc. , today announced that management will participate in three upcoming investor conferences.
BioMarin Pharmaceutical Given Average Recommendation of "Buy" by Brokerages
Shares of BioMarin Pharmaceutical have earned a consensus rating of "Buy" from the seventeen brokerages that are covering the stock, ARN reports .
Fri Aug 15, 2014
BioMarin Pharmaceutical Given Average Rating of "Buy" by Brokerages
BioMarin Pharmaceutical has been given a consensus recommendation of "Buy" by the seventeen analysts that are covering the stock, AmericanBankingNews.com reports .
Thu Aug 07, 2014
Biotech Equities Technical Analysis -- BioMarin Pharma, Merrimack...
However the gains were not broad based as six out of ten sectors ended the session in negative.
Mon Aug 04, 2014
Insider Selling: Daniel K. Spiegelman Sells 2,229 Shares of BioMarin Pharmaceutical Stock
BioMarin Pharmaceutical CFO Daniel K. Spiegelman sold 2,229 shares of the company's stock in a transaction that occurred on Friday, August 1st.
Sat Aug 02, 2014
BioMarin Pharmaceutical PT Raised to $82.00 at Nomura
The firm currently has a "neutral" rating on the stock. Nomura's price objective would suggest a potential upside of 32.36% from the company's current price.
Fri Aug 01, 2014
The Business Journal
BioMarin starts new San Rafael buildings
BioMarin Pharmaceutical, Inc. , is breaking ground on a three-story building at its headquarters campus that will become key to the fast-growing company's pipeline of treatments for rare diseases and disorders.
Wed Jul 30, 2014
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the Companies intend to use a U.S. Food and Drug Administration rare pediatric disease priority review voucher in connection with the Biologics License Application submission for alirocumab.
BioMarin Pharmaceutical (BMRN) Posts Quarterly Earnings, Beats Estimates By $0.18 EPS
BioMarin Pharmaceutical released its earnings data on Wednesday. The company reported EPS for the quarter, beating the Thomson Reuters consensus estimate of by $0.18, AR Network reports.
BioMarin Pharmaceutical Inc. Announces Second Quarter 2014 Financial Results
BioMarin Pharmaceutical Inc. today announced financial results for the second quarter ended June 30, 2014.